Starpharma Holdings (ASX:SPL) Research & Development: A$8.97 Mil (TTM As of Dec. 2025)


ASX:SPL Starpharma Holdings Ltd ASX:SPL
52 GF Score
Price A$0.70
GF Value A$0.43
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Research & Development?

Starpharma Holdings ASX:SPL +0.72% 52 Research & Development is A$8.97 Mil as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 52/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Starpharma Holdings's Research & Development for the six months ended in Dec. 2025 was A$4.95 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$8.97 Mil.

Starpharma Holdings  (ASX:SPL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Starpharma Holdings Research & Development Related Terms

Starpharma Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Research & Development Chart

Starpharma Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.08 11.68 11.24 10.05 8.36

Starpharma Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.26 4.79 4.34 4.02 4.95
ASX:SPL
52GF Score
Starpharma Holdings Ltd ASX:SPL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$8.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$8.97 Mil mean?
Starpharma Holdings (ASX:SPL) has a Research & Development of A$8.97 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Starpharma Holdings and its competitors.
Is Starpharma Holdings' Research & Development too high?
Starpharma Holdings' current Research & Development is A$8.97 Mil. Overall, Starpharma Holdings has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Research & Development compare to VRTX and REGN?
Starpharma Holdings' Research & Development of A$8.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current Research & Development is A$8.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current Research & Development is A$8.97 Mil. Starpharma Holdings' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Research & Development is A$8.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Research & Development: A$8.97 Mil
  • GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
52GF Score

Get the complete analysis for ASX:SPL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.70
Price
A$0.43
GF Value